Sandipan Dawn
Principal Scientist Foghorn Therapeutics
Sandipan has 13+ years of polymer particle chemistry expertise and product development experience in long-acting formulations at Ocular Therapeutics, Living proof and Lubrizol. He played a leadership role in the CMC development of multiple late-stage clinical programs involving controlled release platforms at Ocular Tx as well as development of commercial medical grade polymers / controlled release excipients at Lubrizol.
Sandipan, originally from Calcutta (India), has a PhD in supramolecular organic chemistry from University of South Carolina-Columbia and a post-doc at Conte National Center of Polymer Research at UMass-Amherst on polymer-based DNA delivery and antibody-based cancer adduct detection. He also has a MS in Biotechnology from University of Calcutta and diploma in management from Harvard Business School.
Seminars
- Optimizing LNP design by leveraging targeting ligands for effective organ-specific delivery
- Overcoming physical barriers by addressing particle size limitations to improve penetration into the dense organ specific microenvironment
- Improving stability of targeted LNPs for robust delivery and treatment of oncological indications
